Conference item icon

Conference item

Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?

Abstract:
To estimate the degree to which cardiovascular risk reductions demonstrated with empagliflozin administration in the EMPA-REG OUTCOME trial might be explained by changes observed in conventional cardiovascular factors during the study.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1111/dme.18_13304

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
OCDEM
Role:
Author
Publisher:
Wiley
Host title:
Diabetes UK Professional Conference 2017
Journal:
Diabetes UK Professional Conference 2017 More from this journal
Publication date:
2017-03-01
Acceptance date:
2016-12-21
DOI:
ISSN:
0742-3071
Pubs id:
pubs:721010
UUID:
uuid:d4b2cfd2-3839-4400-aab3-fa8f22152a50
Local pid:
pubs:721010
Source identifiers:
721010
Deposit date:
2017-09-21

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP